Document is current
Any future updates will be listed below
-
Authors
Bandopadhayay, Pratiti
Piccioni, Federica https://orcid.org/0000-0003-1210-3210
O’Rourke, Ryan
Ho, Patricia
Gonzalez, Elizabeth M.
Buchan, Graham
Qian, Kenin
Gionet, Gabrielle
Girard, Emily
Coxon, Margo
Rees, Matthew G. https://orcid.org/0000-0002-2987-7581
Brenan, Lisa
Dubois, Frank
Shapira, Ofer
Greenwald, Noah F. https://orcid.org/0000-0002-7836-4379
Pages, Melanie
Balboni Iniguez, Amanda
Paolella, Brenton R.
Meng, Alice
Sinai, Claire
Roti, Giovanni
Dharia, Neekesh V. https://orcid.org/0000-0001-5048-067X
Creech, Amanda
Tanenbaum, Benjamin
Khadka, Prasidda
Tracy, Adam
Tiv, Hong L. https://orcid.org/0000-0002-5628-3965
Hong, Andrew L. https://orcid.org/0000-0003-0374-1667
Coy, Shannon
Rashid, Rumana
Lin, Jia-Ren https://orcid.org/0000-0003-4702-7705
Cowley, Glenn S. https://orcid.org/0000-0002-0526-0616
Lam, Fred C.
Goodale, Amy
Lee, Yenarae
Schoolcraft, Kathleen
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Tsherniak, Aviad https://orcid.org/0000-0002-3797-1877
Bradner, James E. https://orcid.org/0000-0002-2718-4415
Yaffe, Michael B.
Milde, Till
Pfister, Stefan M.
Qi, Jun
Schenone, Monica https://orcid.org/0000-0002-6456-8768
Carr, Steven A.
Ligon, Keith L.
Kieran, Mark W.
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Olson, James M.
Gokhale, Prafulla C.
Jaffe, Jacob D. https://orcid.org/0000-0001-9845-1210
Root, David E. https://orcid.org/0000-0001-5122-861X
Stegmaier, Kimberly
Johannessen, Cory M.
Beroukhim, Rameen https://orcid.org/0000-0001-6303-3609
- License Information
-
More Information
Article History
Received: 19 October 2018
Accepted: 25 April 2019
First Online: 3 June 2019
Competing interests
: JEB is now an executive and shareholder of Novartis AG, and has been a founder and shareholder of SHAPE (acquired by Medivir), Acetylon (acquired by Celgene), Tensha (acquired by Roche), Syros, Regency and C4 Therapeutics. A.G., R.B., and K.S. also consulted for Novartis. P.B., K.S., and R.B. receive grant funding from Novartis. MWK is now an employee of Bristol Myer Squibb and C.M.J. is now an employee of Novartis. W.C.H. is a consultant for Thermo Fisher, AjuIB, Parexel, MPM and is a founder and advisor to K.S.Q. Therapeutics. SS consulted for Rarecyte, Inc. All other authors declare no competing interests.
